Type 2 Diabetes
Conditions
Brief summary
The main objective of the study is to investigate if resveratrol supplementation can improve overall and muscle-specific insulin sensitivity in type 2 diabetic patients. As a secondary objective the investigators want to investigate whether the improved insulin sensitivity can be attributed to improved muscle mitochondrial oxidative capacity and a reduced intrahepatic and cardiac lipid content.
Interventions
DIETARY_SUPPLEMENTplacebo
A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
DIETARY_SUPPLEMENTresveratrol
resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
Sponsors
DSM Nutritional Products, Inc.
Maastricht University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male sex * Age: 40-70 years * Body fat percentage \> 25, BMI 27-35 kg/m2 * Diagnosed with type 2 diabetes at least one year before the start of the study * Well-controlled type 2 diabetics: HBA1C \< 8.0% * Oral glucose lowering medication (metformin only or in combination with sulfonylurea agents) * Sedentary * Not more than 2 hours of sports a week * No active job that requires strenuous physical activity * Stable dietary habits * Willingness to abstain from resveratrol-containing food products
Exclusion criteria
* Unstable body weight (weight gain or loss \> 3kg in the last three months) * Total body fat percentage \< 25% * Hemoglobin \< 7.8 mmol/l * Use of anticoagulants * Engagement in programmed exercise \> 2 hours total per week * Impaired kidney and/or hepatic function Creatinine 50-100 umol/L Liver enzymes, within 2 times of normal range of laboratory standard (ASAT \< 60 U/L, ALAT \< 70 U/L, Billi \<40 umol/L, gamma-GT \< 80 U/L) * No diabetes related co-morbidities like cardiovascular diseases, diabetic foot, polyneuropathy, retinopathy * Insulin dependent Diabetic subjects * Any medical condition except type 2 diabetes mellitus requiring treatment and/or medication use except metformin only or in combination with sulfonylurea agents * Intake of dietary supplements except multivitamins and minerals * Current alcohol consumption \> 20 grams/day * Subjects who don't want to be informed about unexpected medical findings during the screening /study, or do not wish that their physician is informed, cannot participate in the study. * Participation in another biomedical study within 1 month before the first screening visit * Any contraindication to MRI scanning. These contra-indications include patients with following devices: * Central nervous system aneurysm clip * Implanted neural stimulator * Implanted cardiac pacemaker of defibrillator * Cochlear implant * Insulin pump * Or metal containing corpora aliena in the eye or brains
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| insulin sensitivity (overall, muscle- and liver specific) | 30 days after supplementation |
Secondary
| Measure | Time frame |
|---|---|
| muscle mitochondrial oxidative capacity | 30 days after supplementation |
| intramyocellular lipid content | 30 days after supplementation |
| intrahepatic lipid content | 30 days after supplementation |
| intracardiac lipid content | 30 days after supplementation |
| heart function | 30 days after supplementation |
Countries
Netherlands
Outcome results
None listed